After a year on the rise, the pharmaceutical industry's reputation is now down 15% from its peak 
achieved at the end of 2020. This is what emerges from the survey data of the American company Harris Poll this month, which show that Americans view the industry in a less positive light.
The 47% of the interviewees expresses a good opinion of the sector, down compared to the 62% of the end of 2020, when vaccines were authorized to mRNA against the COVID-19. And it's also down on the 50% surveyed earlier this year.
The economy and war would have a negative impact on reputation, at a time when COVID-19 is moving from a pandemic to an endemic disease. Therefore, according to experts, interest in the pharmaceutical industry is simply slipping into the background.
Respondents are more concerned about the threat of a wider conflict and have begun to lose interest in pharmaceuticals, returning to patterns and popularity prior to the outbreak of the pandemic. In any case, pharmaceutical reputation is still higher than it was at any point in the decade before the pandemic, when the popularity rating hovered around 30%.
DAILY HEALTH INDUSTRY – March 21, 2022
___________________________
From Harris Poll
Audience viewing in nearly every industry has improved since the onset of the coronavirus pandemic, according to a new Axios/Harris survey. Industries with a prominent role in quarantine living have seen particularly large jumps
The survey ranks the top 100 companies, based on consumer scores in 7 qualities: affinity (trust), citizenship, ethics, culture, vision, growth, and products and services. Affinity carries more weight than all other categories.
The Axios Harris Poll 100 is based on a survey of 42,935 Americans in a nationally representative sample. The two-step process starts afresh each year by examining public awareness of companies that excel or falter in society. These 100 "Most Visible Companies" are then rated by a second group of Americans across the seven key dimensions of reputation to determine rankings. If a company isn't on the list, it hasn't reached a critical level of visibility to measure.
THEReports
